Sclerosing Cholangitis as ImmuneRelated Adverse Event Caused by Nivolumab and Ipilimumab Therapy
Case Report | Open Access
Volume 9 | Issue 1 |
Article DOI : https://doi.org/10.47739/2373-9371/1139
Loading
Katsuie S, Nakamura K, Suzuki R, Nihei T, Takazawa Y, et al. (2021) Sclerosing Cholangitis as Immune-Related Adverse Event Caused by Nivolumab and Ipilimumab Therapy. J Dermatolog Clin Res 9(1): 1139.